At present, a diversity of DYRK1A inhibitors were identified as potential therapies for neurodegenerative diseases including natural product harmine and synthetic compounds, benzothiazoles, azaindoles, pyrazolo, pyridine, pyrimidine, and quinazolines [5,6]. The gene discussed is DYRK1A; the disease is neurodegenerative disease.